News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
551,806 Results
Type
Article (41619)
Company Profile (125)
Press Release (510062)
Multimedia
Podcasts (62)
Webinars (10)
Section
Business (146015)
Career Advice (1997)
Deals (28626)
Drug Delivery (89)
Drug Development (73028)
Employer Resources (147)
FDA (14365)
Job Trends (12172)
News (265449)
Policy (25713)
Tag
Academia (2549)
Accelerated approval (6)
Adcomms (26)
Allergies (78)
Alliances (37741)
ALS (89)
Alzheimer's disease (1332)
Antibody-drug conjugate (ADC) (122)
Approvals (14362)
Artificial intelligence (239)
Autoimmune disease (26)
Automation (14)
Bankruptcy (261)
Best Places to Work (10139)
BIOSECURE Act (16)
Biosimilars (76)
Biotechnology (80)
Bladder cancer (82)
Brain cancer (28)
Breast cancer (259)
Cancer (2184)
Cardiovascular disease (184)
Career advice (1665)
Career pathing (32)
CAR-T (145)
Cell therapy (401)
Cervical cancer (18)
Clinical research (59731)
Collaboration (746)
Compensation (342)
Complete response letters (24)
COVID-19 (2446)
CRISPR (39)
C-suite (213)
Cystic fibrosis (100)
Data (2141)
Decentralized trials (1)
Denatured (13)
Depression (45)
Diabetes (251)
Diagnostics (5617)
Digital health (14)
Diversity (3)
Diversity, equity & inclusion (39)
Drug discovery (110)
Drug pricing (91)
Drug shortages (26)
Duchenne muscular dystrophy (94)
Earnings (55587)
Editorial (41)
Employer branding (21)
Employer resources (129)
Events (77901)
Executive appointments (607)
FDA (15547)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (744)
Gene editing (101)
Generative AI (19)
Gene therapy (321)
GLP-1 (713)
Government (4124)
Grass and pollen (4)
Guidances (63)
Healthcare (16827)
Huntington's disease (22)
IgA nephropathy (30)
Immunology and inflammation (118)
Indications (28)
Infectious disease (2588)
Inflammatory bowel disease (127)
Inflation Reduction Act (7)
Influenza (49)
Intellectual property (83)
Interviews (332)
IPO (14162)
IRA (37)
Job creations (2414)
Job search strategy (1432)
Kidney cancer (10)
Labor market (29)
Layoffs (378)
Leadership (20)
Legal (4948)
Liver cancer (73)
Lung cancer (320)
Lymphoma (148)
Machine learning (5)
Management (47)
Manufacturing (281)
MASH (73)
Medical device (11304)
Medtech (11308)
Mergers & acquisitions (15004)
Metabolic disorders (680)
Multiple sclerosis (79)
NASH (21)
Neurodegenerative disease (92)
Neuropsychiatric disorders (30)
Neuroscience (1862)
NextGen: Class of 2025 (5812)
Non-profit (4162)
Now hiring (34)
Obesity (363)
Opinion (239)
Ovarian cancer (72)
Pain (87)
Pancreatic cancer (78)
Parkinson's disease (135)
Partnered (17)
Patents (194)
Patient recruitment (108)
Peanut (45)
People (43405)
Pharmaceutical (41)
Pharmacy benefit managers (13)
Phase I (17868)
Phase II (26526)
Phase III (20301)
Pipeline (1169)
Policy (130)
Postmarket research (2234)
Preclinical (7536)
Press Release (56)
Prostate cancer (104)
Psychedelics (28)
Radiopharmaceuticals (270)
Rare diseases (405)
Real estate (4214)
Recruiting (59)
Regulatory (18640)
Reports (36)
Research institute (2207)
Resumes & cover letters (309)
Rett syndrome (5)
RNA editing (5)
RSV (45)
Schizophrenia (72)
Series A (139)
Series B (88)
Service/supplier (7)
Sickle cell disease (48)
Special edition (12)
Spinal muscular atrophy (152)
Sponsored (24)
Startups (3570)
State (2)
Stomach cancer (12)
Supply chain (61)
Tariffs (34)
The Weekly (48)
Vaccines (675)
Venture capitalists (43)
Weight loss (247)
Women's health (28)
Worklife (15)
Date
Today (162)
Last 7 days (765)
Last 30 days (2320)
Last 365 days (28985)
2025 (9390)
2024 (30945)
2023 (34635)
2022 (44580)
2021 (48306)
2020 (46808)
2019 (40424)
2018 (30631)
2017 (28054)
2016 (26641)
2015 (30975)
2014 (22867)
2013 (18514)
2012 (19656)
2011 (20396)
2010 (18311)
Location
Africa (687)
Alabama (45)
Alaska (5)
Arizona (125)
Arkansas (11)
Asia (32896)
Australia (5839)
California (5182)
Canada (1740)
China (481)
Colorado (230)
Connecticut (252)
Delaware (117)
Europe (76026)
Florida (800)
Georgia (169)
Idaho (42)
Illinois (474)
India (24)
Indiana (234)
Iowa (6)
Japan (156)
Kansas (93)
Kentucky (15)
Louisiana (10)
Maine (47)
Maryland (759)
Massachusetts (3789)
Michigan (183)
Minnesota (254)
Mississippi (2)
Missouri (60)
Montana (23)
Nebraska (22)
Nevada (49)
New Hampshire (49)
New Jersey (1524)
New Mexico (21)
New York (1528)
North Carolina (839)
North Dakota (7)
Northern California (2254)
Ohio (177)
Oklahoma (10)
Oregon (33)
Pennsylvania (1134)
Puerto Rico (10)
Rhode Island (30)
South America (962)
South Carolina (14)
South Dakota (1)
Southern California (1982)
Tennessee (77)
Texas (769)
United States (19468)
Utah (143)
Virginia (140)
Washington D.C. (42)
Washington State (493)
West Virginia (2)
Wisconsin (49)
551,806 Results for "ra capital associates".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management
Medicenna Therapeutics Corp. announced the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement.
April 30, 2024
·
5 min read
Press Releases
Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting
April 29, 2025
·
7 min read
Press Releases
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting
April 30, 2025
·
8 min read
Press Releases
Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
March 25, 2025
·
11 min read
Biotech Bay
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
Vaxart, Inc. announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.
January 16, 2024
·
6 min read
Press Releases
Vividion Therapeutics Doses First Patient in Phase I Study of RAS-PI3Kα Inhibitor for Treatment of Advanced Solid Tumors
April 3, 2025
·
5 min read
Biotech Beach
Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting
Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.
April 10, 2024
·
3 min read
Press Releases
Cardiff Oncology Announces Completion of Enrollment in Phase 2 CRDF-004 Trial Evaluating Onvansertib for the Treatment of First-line RAS-mutated Metastatic Colorectal Cancer
April 15, 2025
·
4 min read
Press Releases
ORYZON Raises €30 Million in Capital Increase
April 25, 2025
·
9 min read
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
1 of 55,181
Next
